Study 3 – Intravenous injection of Toca 511 with subsequent Toca 511 injection at the time of tumor removal

This study focuses on patients with recurrent high grade glioma who have decided to have surgery to remove their tumor. In order to participate in this study, the tumor recurrence must measure less than 8 cm in its greatest dimension and the surgeon estimates that at least 80% of the tumor can be removed at surgery. Patients will receive one half of the Toca 511 dose intravenously, followed approximately 11 days later by removal of the tumor and injection of the remaining half of the Toca 511 dose into the wall of the resection cavity. The tumor specimen will be tested for the presence of Toca 511. Approximately 4 weeks after injection of Toca 511 at the time of surgery, subjects will begin a course of oral Toca FC. If tolerated, these courses of Toca FC will be repeated. The focus of this study is to assess the safety and tolerability of Toca 511 & Toca FC. Gadolinium-enhanced MRI scan will be performed every two months for 6 months to assess the effect of treatment.

A patient may qualify for this study if the patient:

  • Has a recurrent high grade glioma (Grade 3 or Grade 4)
  • Has had prior surgery, radiation and chemotherapy
  • Is at least 18 years of age

Patient Inquiry for Intravenous Study
Learn more about our brain cancer programs.